280 related articles for article (PubMed ID: 28866292)
1. The road to a more effective influenza vaccine: Up to date studies and future prospects.
Sano K; Ainai A; Suzuki T; Hasegawa H
Vaccine; 2017 Sep; 35(40):5388-5395. PubMed ID: 28866292
[TBL] [Abstract][Full Text] [Related]
2. Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
Tamura S; Ainai A; Suzuki T; Kurata T; Hasegawa H
Jpn J Infect Dis; 2016; 69(3):165-79. PubMed ID: 27212584
[TBL] [Abstract][Full Text] [Related]
3. Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.
He W; Mullarkey CE; Duty JA; Moran TM; Palese P; Miller MS
J Virol; 2015 Apr; 89(7):3610-8. PubMed ID: 25589655
[TBL] [Abstract][Full Text] [Related]
4. Intranasal Administration of Whole Inactivated Influenza Virus Vaccine as a Promising Influenza Vaccine Candidate.
Ainai A; Suzuki T; Tamura SI; Hasegawa H
Viral Immunol; 2017; 30(6):451-462. PubMed ID: 28650274
[TBL] [Abstract][Full Text] [Related]
5. Human genetics and responses to influenza vaccination: clinical implications.
Lambkin R; Novelli P; Oxford J; Gelder C
Am J Pharmacogenomics; 2004; 4(5):293-8. PubMed ID: 15462607
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal analysis of the peripheral B cell repertoire reveals unique effects of immunization with a new influenza virus strain.
Cortina-Ceballos B; Godoy-Lozano EE; Téllez-Sosa J; Ovilla-Muñoz M; Sámano-Sánchez H; Aguilar-Salgado A; Gómez-Barreto RE; Valdovinos-Torres H; López-Martínez I; Aparicio-Antonio R; Rodríguez MH; Martínez-Barnetche J
Genome Med; 2015 Nov; 7():124. PubMed ID: 26608341
[TBL] [Abstract][Full Text] [Related]
7. Characterization of neutralizing antibodies in adults after intranasal vaccination with an inactivated influenza vaccine.
Ainai A; Tamura S; Suzuki T; Ito R; Asanuma H; Tanimoto T; Gomi Y; Manabe S; Ishikawa T; Okuno Y; Odagiri T; Tashiro M; Sata T; Kurata T; Hasegawa H
J Med Virol; 2012 Feb; 84(2):336-44. PubMed ID: 22170556
[TBL] [Abstract][Full Text] [Related]
8. Intranasal inactivated influenza vaccines for the prevention of seasonal influenza epidemics.
Sano K; Ainai A; Suzuki T; Hasegawa H
Expert Rev Vaccines; 2018 Aug; 17(8):687-696. PubMed ID: 30092690
[TBL] [Abstract][Full Text] [Related]
9. Neuraminidase antibody response to inactivated influenza virus vaccine following intranasal and intramuscular vaccination.
Muhamed G; Greenbaum E; Zakay-Rones Z
Isr Med Assoc J; 2006 Mar; 8(3):155-8. PubMed ID: 16599048
[TBL] [Abstract][Full Text] [Related]
10. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
[TBL] [Abstract][Full Text] [Related]
11. A novel H6N1 virus-like particle vaccine induces long-lasting cross-clade antibody immunity against human and avian H6N1 viruses.
Yang JR; Chen CY; Kuo CY; Cheng CY; Lee MS; Cheng MC; Yang YC; Wu CY; Wu HS; Liu MT; Hsiao PW
Antiviral Res; 2016 Feb; 126():8-17. PubMed ID: 26593980
[TBL] [Abstract][Full Text] [Related]
12. Induction of Local Secretory IgA and Multifunctional CD4⁺ T-helper Cells Following Intranasal Immunization with a H5N1 Whole Inactivated Influenza Virus Vaccine in BALB/c Mice.
Trondsen M; Aqrawi LA; Zhou F; Pedersen G; Trieu MC; Zhou P; Cox RJ
Scand J Immunol; 2015 May; 81(5):305-17. PubMed ID: 25737202
[TBL] [Abstract][Full Text] [Related]
13. Intranasal vaccination with a replication-deficient influenza virus induces heterosubtypic neutralising mucosal IgA antibodies in humans.
Morokutti A; Muster T; Ferko B
Vaccine; 2014 Apr; 32(17):1897-900. PubMed ID: 24560674
[TBL] [Abstract][Full Text] [Related]
14. Call for a paradigm shift in the design of universal influenza vaccines by harnessing multiple correlates of protection.
Jang YH; Seong BL
Expert Opin Drug Discov; 2020 Dec; 15(12):1441-1455. PubMed ID: 32783765
[TBL] [Abstract][Full Text] [Related]
15. Hemagglutinin-specific CD4
Tan S; Zhang S; Wu B; Zhao Y; Zhang W; Han M; Wu Y; Shi G; Liu Y; Yan J; Wu G; Wang H; Gao GF; Zhu F; Liu WJ
Vaccine; 2017 Oct; 35(42):5644-5652. PubMed ID: 28917539
[TBL] [Abstract][Full Text] [Related]
16. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
[TBL] [Abstract][Full Text] [Related]
17. Aerosol Delivery of a Candidate Universal Influenza Vaccine Reduces Viral Load in Pigs Challenged with Pandemic H1N1 Virus.
Morgan SB; Hemmink JD; Porter E; Harley R; Shelton H; Aramouni M; Everett HE; Brookes SM; Bailey M; Townsend AM; Charleston B; Tchilian E
J Immunol; 2016 Jun; 196(12):5014-23. PubMed ID: 27183611
[TBL] [Abstract][Full Text] [Related]
18. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
19. An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with Infection.
Lambkin-Williams R; Gelder C; Broughton R; Mallett CP; Gilbert AS; Mann A; He D; Oxford JS; Burt D
PLoS One; 2016; 11(12):e0163089. PubMed ID: 28005959
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans.
Zhong W; Gross FL; Holiday C; Jefferson SN; Bai Y; Liu F; Katz JM; Levine MZ
Viral Immunol; 2016 May; 29(4):259-62. PubMed ID: 26950058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
